» Articles » PMID: 29127553

Identification of Histidine 303 As the Catalytic Base of Lysyl Oxidase Via Site-Directed Mutagenesis

Overview
Journal Protein J
Publisher Springer
Specialty Biochemistry
Date 2017 Nov 12
PMID 29127553
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Lysyl oxidase (LOX) is a copper-dependent amine oxidase enzyme that catalyzes the formation of crosslinkages of collagen and elastin in connective tissues by oxidative deamination of lysine. Using site-directed mutagenesis, Histidine 303 has been shown to be a key residue that acts as the necessary catalytic base for this enzyme to function properly. Histidine 303 was mutated to isoleucine to remove catalytic activity and to aspartate and glutamate, respectively, in order to provide alternate residues that could act as a general base that could maintain catalytic activity. Overexpression of the H303I mutant yielded 3.9 mg of enzyme per liter of media, the H303D mutant yielded 3.3 mg of enzyme per liter of media, and the H303E mutant yielded 3.0 mg/L of media. Overexpression of wildtype LOX yielded 4.5 mg/L of media, which is a slight improvement from previous yields. Total copper incorporation for H303I was calculated to be 68% and no copper was detected for the H303D and H303E mutants. As LOX requires the self-processed cofactor lysyl tyrosyl quinone (LTQ) for activity, total LTQ content was obtained by reacting the enzyme with phenylhydrazine and using the previously reported extinction coefficient of 15.4 mM/cm. LTQ content for the wildtype enzyme was determined to be 92%, for H303I the total LTQ content was determined to be 36%, and no LTQ was detected for the H303D and H303E mutants. No catalytic activity was detected for any mutants when compared to the wildtype which has a previously reported activity of 0.11 U/mg. Comparison of excitation-emission matrices (EEM) of each of the mutants as compared to the wildtype indicate that all the mutations cause a change in the internal environment of the enzyme, albeit to varying degrees, as evidenced by the observed shifts.

Citing Articles

Lysyl oxidase-like 4 exerts an atypical role in breast cancer progression that is dependent on the enzymatic activity that targets the cell-surface annexin A2.

Komalasari N, Tomonobu N, Kinoshita R, Chen Y, Sakaguchi Y, Gohara Y Front Oncol. 2023; 13:1142907.

PMID: 37091157 PMC: 10114587. DOI: 10.3389/fonc.2023.1142907.


LOX inhibition downregulates MMP-2 and MMP-9 in gastric cancer tissues and cells.

Zhao L, Niu H, Liu Y, Wang L, Zhang N, Zhang G J Cancer. 2019; 10(26):6481-6490.

PMID: 31777578 PMC: 6856903. DOI: 10.7150/jca.33223.


A Three-Dimensional Model of Human Lysyl Oxidase, a Cross-Linking Enzyme.

Vallet S, Gueroult M, Belloy N, Dauchez M, Ricard-Blum S ACS Omega. 2019; 4(5):8495-8505.

PMID: 31459939 PMC: 6647939. DOI: 10.1021/acsomega.9b00317.

References
1.
Lopez K, Greenaway F . Identification of the copper-binding ligands of lysyl oxidase. J Neural Transm (Vienna). 2010; 118(7):1101-9. DOI: 10.1007/s00702-010-0559-4. View

2.
Smyth D, Mrozkiewicz M, McGrath W, Listwan P, Kobe B . Crystal structures of fusion proteins with large-affinity tags. Protein Sci. 2003; 12(7):1313-22. PMC: 2323919. DOI: 10.1110/ps.0243403. View

3.
Kagan H, Li W . Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003; 88(4):660-72. DOI: 10.1002/jcb.10413. View

4.
Cox T, Gartland A, Erler J . Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis. Cancer Res. 2016; 76(2):188-92. DOI: 10.1158/0008-5472.CAN-15-2306. View

5.
Smith M, Gonzalez J, Hussain A, Oldfield R, Johnston K, Lopez K . Overexpression of Soluble Recombinant Human Lysyl Oxidase by Using Solubility Tags: Effects on Activity and Solubility. Enzyme Res. 2016; 2016:5098985. PMC: 4753049. DOI: 10.1155/2016/5098985. View